ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Claritev Further Strengthens Leadership Team as Part of Business Transformation Strategy

Jigar S. Patel, MD, Named Chief Medical Officer

Fernando Schwartz, Ph.D., Named Chief Artificial Intelligence Officer

Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the following newly created appointments to its senior leadership team to support the company’s strategic growth, transformation and mission to bring transparency to the healthcare ecosystem with innovative products and solutions.

Jigar S. Patel, MD, has been appointed Chief Medical Officer effective April 14, 2025. As a new member of the Executive Leadership Team, Patel will provide medical guidance on the strategic development and product innovation of Claritev’s healthcare technology and network optimization solutions. Patel brings deep expertise in healthcare delivery, medical network dynamics and industry relationships. This experience will be integral as he works to align Claritev’s products with the evolving needs of the industry, including health plans, payors and other medical organizations. Prior to joining Claritev, Patel spent more than 18 years at Cerner/Oracle where he worked with large national healthcare companies on all aspects of their Healthcare Information Technology needs and strategy.

Fernando Schwartz, Ph.D., has been appointed Chief Artificial Intelligence Officer effective February 17, 2025. Schwartz leads the AI and Data Science Department on Chief Digital Officer Michael Kim’s team. Bringing 15 years of leadership in data science and machine learning, Schwartz will lead the Company’s AI and analytics strategy as well as new product development and capabilities that will benefit existing and new clients or partners. Prior to joining Claritev, Schwartz most recently served as the Vice President of AI at ADP. Before that, he led the global data science strategy for Merck’s Human Health Division as the Associate Vice President and Global Head of Data Science.

“Today’s announcement marks a pivotal moment in Claritev’s strategic transformation journey,” said Travis Dalton, Chairman, CEO and President of Claritev. “With their past industry experience and expertise, Jigar’s and Fernando’s roles will bring us a step closer to providing cutting-edge innovation and technology that promote more affordable, transparent and higher quality healthcare services.

About Claritev

Claritev, formerly known as MultiPlan, is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the U.S. healthcare system. Led by a team of deeply experienced associates, data scientists, and innovators, Claritev provides cutting-edge solutions and services fueled by over 40 years of claims processing data. Claritev leverages world-class technology and AI to power a robust enterprise platform that delivers meaningful insights to drive affordability and price transparency, and optimizes networks and benefits design in healthcare. By developing purpose-build solutions that support all key stakeholders – including payors, employers, patients, providers, and third parties – Claritev is dedicated to making healthcare more accessible and affordable for all.

Claritev serves more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers. For more information, visit claritev.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.